semaglutide weight gain How To Avoid After Stopping Simple “gut reset” may stop

In March 2024, the FDA approved a new indication for use for Wegovy (semaglutide): to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight

Today, my most troubling clinical dilemma is ironically due to excess GLP-1s: Im trying to slow down runaway trains, and even spot them before they leave the station

16 , 47 However, a reliable estimation can be made by comparing brain uptake after intranasal and intravenous administration

In my experience looking at this, the fatigue is worst on days two and three after the first injection, then improves

That does not mean it has no effect, but it does mean the evidence should be evaluated honestly rather than through clinic marketing

M.TokarevJ